Sixfold Bioscience GTM brain

category

market profile

• text: Reaching cell types beyond liver hepatocytes remains a major challenge for RNA therapeutics developers.
• text: Sixfold describes Mergo as an RNA tag developed using computation and screened for delivery to selected cell types; the work is preclinical.

personas

• title: Head of RNA delivery or oligonucleotide R&D
  pains:

  • A promising RNA payload cannot reach its intended extrahepatic cell population reliably.
  • Developing and testing delivery candidates across biological models consumes time and experimental capacity.
• title: Pharmaceutical business development or external innovation leader
  pains:

  • Programs require access to delivery technology beyond the company's internal expertise.
  • Any collaboration must establish tissue-specific evidence, development responsibilities and rights.
• title: Preclinical translational science director
  pains:

  • Cell-specific biodistribution, efficacy and safety must be demonstrated before investing in clinical development.
  • Scale-up and manufacturability must be addressed early.

icp

• text: Biotech and pharmaceutical R&D organizations developing siRNA or mRNA therapeutics are prospective research and development partners.
• text: Teams pursuing target cells outside the liver, especially those with an existing RNA payload and delivery bottleneck, are likely fits; this is an inference from the platform's stated focus.

message pillars

• text: Frame delivery as the constraint on new RNA therapies.
• text: Draw on naturally occurring RNA transport mechanisms.
• text: Use machine learning to generate and screen delivery candidates.

objections

• objection: Can Mergo reach our target tissue safely and reproducibly?
  response: Request payload-specific biodistribution, efficacy and safety data and define a joint preclinical evaluation. Public claims do not establish results for every target.
• objection: Can a novel delivery construct be manufactured at scale?
  response: Review synthesis, quality control, scale-up and reproducibility evidence for the specific construct and development stage.

competitors

• name: Silence Therapeutics
  why: Develops siRNA medicines and delivery conjugates, an alternative approach to targeting RNA therapies.
• name: RNA Nanobiotics
  why: Develops RNA delivery technologies and lists Sixfold among competing delivery approaches.

influencers

• name: Anna Perdrix Rosell
  url: https://www.bioindustry.org/resource/sixfold-bioscience-presents-at-uk-governments-office-for-life-sciences.html
  why: Co-founder and co-CEO who speaks publicly about the RNA delivery challenge.

keywords

• RNA delivery platform
• extrahepatic RNA delivery
• siRNA delivery
• targeted RNA therapeutics
• RNA delivery collaboration
• cell specific RNA delivery

voice

• Scientific
• Ambitious
• Nature-inspired

signals

• text: A drug developer launches an RNA program targeting a cell type outside the liver.
• text: A biotech seeks a collaborative R&D partner for RNA delivery construct design and screening.

pricing

motion

channels

• industry conferences
• research partnerships
• scientific media

confidence

Founders

• name: George Foot
  title: Founder
  role: Founder
• name: Anna Perdrix Rosell
  title: Founder
  role: Founder